RA

Rishi Anand

Active Director Director DIN 08944867
DIN 08944867 First appointment Oct 2020 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2020
Shareholding value •••• Premium profile

About Rishi Anand

Data last updated:

Rishi Anand is a Director at Aster Medicines Private Limited (since 2020). The company operates in Pharma. Aster Medicines Private Limited reported revenue of ₹13.00 Cr (FY 2025).

DIN 08944867
Primary Designation Director
Industry Pharma
First Appointment 23 Oct 2020
Oldest Company Age 18 yrs
Largest company Aster Medicines Private Limited · ₹13.00 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Aster Medicines Private Limited U24230BR2008PTC013937
Director23 Oct 20202008₹13.00 Cr (FY 2025)Active

Board colleagues of Rishi Anand

NameDINCompanyDesignation
Rupesh Anand02265226Aster Medicines Private LimitedManaging Director

Directorship timeline

Open interactive timeline →
Aster Medicines Private Limited
Premium access

Shareholding and investment profile for Rishi Anand

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rishi Anand

Rishi Anand currently holds 1 directorship: Aster Medicines Private Limited (Director, since 23 Oct 2020, revenue ₹13.00 Cr (FY 2025)).

Rishi Anand was first appointed on 23 Oct 2020 as Director at Aster Medicines Private Limited.

The current boards of Rishi Anand's companies include Rupesh Anand (Aster Medicines Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available